摘要
目的:观察甲磺酸阿帕替尼(Apatinib)二线治疗晚期胃癌的疗效和安全性。方法:回顾性分析弋矶山医院经一线化疗后进展的晚期胃癌患者46例,设为实验组和对照组,其中实验组(阿帕替尼组)24例,对照组(化疗组)22例。均接受至少2周期的治疗,评价临床疗效及生存分析,观察毒副反应。结果:两组对比RR(χ2=0.033,P=0.875)和DCR(χ2=0.763,P=0.382),差异无统计学意义;实验组PFS对比对照组,差异有统计学意义(χ2=4.195,P=0.041);毒副反应方面对照组白细胞减少、神经毒性、呕吐、脱发发生率高于实验组(P<0.05)。结论:阿帕替尼二线治疗晚期胃癌的近期疗效及mOS和化疗对照组相当,mPFS延长,且毒副反应可耐受。
Objective:To evaluate clinical effect and safety of apatinib as second-line target treatment for advanced gastric cancer.Methods:Retrospective analysis was performed in 46 cases of advanced gastric cancer with advanced disease following first-line chemotherapy.The patients were randomly divided into observational group(n=24,treated with apatinib)and control group(n=22,treated with chemotherapy agent),and received at least two courses of medication.Then the two groups were subjected to evaluation of clinical efficacies,survival and incidence of adverse reactions.Results:The difference was insignificant in response rate(RR)and disease control rate(DCR)(χ2=0.033,P=0.875;χ2=0.763,P=0.382,respectively),yet significant in progression-free survival(PFS)between groups(χ2=4.195,P=0.041).Control group had higher incidences of aleucocytosis,neurotoxicity,vomiting and alopecic than the observational group(P<0.05).Conclusion:Apatinib as second-line treatment for advanced gastric cancer can lead to similar short-term effect with chemotherapy by median overall survival(mOS)and prolonged median PFS.The toxicity is maintained within acceptable limit.
作者
何杨
朱益平
彭玉珍
吉兆宁
HE Yang;ZHU Yiping;PENG Yuzhen;JI Zhaoning(Department of Medical Oncology,The First Affiliated Hospital of Wannan Medical College,Wuhu 241001,China)
出处
《皖南医学院学报》
CAS
2020年第1期36-40,共5页
Journal of Wannan Medical College
基金
安徽省高校自然科学研究项目(KJ2017A262)。
关键词
甲磺酸阿帕替尼
化疗
晚期胃癌
apatinib mesylate
chemotherapy
advanced gastric cancer
